Take Solutions Limited has released its financial results for the second quarter of FY26, showcasing an improved bottom line even though the company generated no operational revenue during the period. A sharp turnaround driven by discontinued operations has notably influenced investor sentiment.
Q2 FY26 Performance Highlights
The company declared its Q2 numbers on October 27, 2025. Take Solutions posted a consolidated net profit of ₹6.29 crore, a meaningful recovery from the ₹1.58 crore loss recorded in the same quarter of the previous year. The result also contrasts with the ₹0.91 crore loss reported in Q1 FY26, signalling a positive reversal in quarterly performance.
Operational revenue remained at zero, consistent with the same quarter last year. In comparison, the company had reported a marginal income of ₹0.04 crore in the June quarter.
Turnaround Fueled by Discontinued Operations
The profit revival stems largely from gains linked to the company’s discontinued units, particularly its wholly owned subsidiary Ecron Acunova Limited (EAL). The accounting impact from these segments played a decisive role in shifting the company back into profitability and offsetting losses seen in recent quarters.
Company Overview
Established in 2000 and headquartered in Chennai, Take Solutions operates across the Life Sciences and Supply Chain Management domains. Its offerings include clinical research services, pharmacovigilance support, bioequivalence studies, regulatory consulting, and technology-led supply chain solutions. The company has a broad footprint spanning India, the US, Europe, and other overseas markets, supported by domain expertise and proprietary platforms.
Summary
Take Solutions returned to profitability in Q2 FY26 with a net profit of ₹6.29 crore, driven primarily by discontinued operations, even as operational revenue remained absent. The financial turnaround underscores the impact of subsidiary-related gains and marks a notable improvement over previous quarters.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.